Future aspects of the treatment of pulmonary arterial hypertension;Zukunftsaspekte der therapie der pulmonalarteriellen hypertonie

Deutsche Medizinische Wochenschrift

Volumn 131, Issue 49 SUPPL. 9, 2006, Pages

  Ghofrani, H Ardeschir ^a   Rosenkranz, S ^b   Grimminger, F ^a  

^a UNIVERSITY HOSPITAL GIESSEN   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 1; CALCIUM CHANNEL BLOCKING AGENT; CYCLIC AMP; CYCLIC GMP; ELASTASE INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; GUANYLATE CYCLASE; IMATINIB; PHOSPHODIESTERASE V INHIBITOR; PROSTANOID; PROTEIN TYROSINE KINASE INHIBITOR; RHO KINASE INHIBITOR; SEROTONIN ANTAGONIST; TETRAHYDROBIOPTERIN;

CARDIOTOXICITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DRUG MECHANISM; ENZYME ACTIVATION; GENE THERAPY; HUMAN; MONOTHERAPY; PATHOPHYSIOLOGY; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK BENEFIT ANALYSIS; TREATMENT PLANNING;

ANIMALS; DRUG THERAPY; ENZYME ACTIVATORS; GUANYLATE CYCLASE; HUMANS; HYPERTENSION, PULMONARY; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; VASODILATOR AGENTS;

EID: 33846287240     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-957207     Document Type: Review

References (14)

1. Austin S. Drug discovery technology Europe 2006 - ICB's Tenth Annual Conference and Exhibition. Drugs 2006; 9: 256-260
2. Dumitrascu R, Weissmann N, Ghofrani HA, Dony E, Beuerlein K, Schmidt H, Stasch JP, Gnoth MJ, Seeger W, Grimminger F, Schermuly RT. Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling. Circulation 2006; 113: 286-295
3. Evgenov OV, Pacher P, Schmidt PM, Hasko G, Schmidt HH, Stasch JP. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov 2006; 5: 755-768
4. Ghofrani HA, Schermuly RT, Weissmann N, Seeger VJ, Grimminger F. "Reverse remodelling" - Paradigmenwechsel in der Behandlung der pulmonalen Hypertonie. Dtsch Med Wochenschr 2006; 131: 871-874
5. Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 2005; 353: 1412-1413
6. Kerkelä R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, Walters B, Shevtsov S, Pesants, Clubb FJ et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006 [E-pub ahead of print].
7. Murray F, Patel HH, Suda RYS et al. Expression and activity of cAMP phosphodiesterase isoforms in pulmonary artery smooth muscle cells from patients with pulmonary hypertension: Role of PDE1. Am J Physiol Lung Cell Mol Physiol 2006 [E-pub ahead of print).
8. Newman JH, Fanburg BL, Archer SL, Badesch DB, Barst RJ, Garcia JG, Kao PN, Knowles JA, Loyd JE, McGoon MD, Morse JH, Nichols WC, Rabinovitch M, Rodman DM, Stevens T, Tuder RM, Voelkel NF, Gail DB National Heart, Lung and Blood Institute/Office of Rare Diseases. Pulmonary arterial hypertension: Future directions: Report of a National Heart, Lung and Blood Institute/Office of Rare Diseases workshop. Circulation 2004; 109: 2947-2952
9. Patterson KC, Weissmann A, Ahmadi T, Farber HW. Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension. Ann Intern Med 2006; 145: 152-153
10. Phillips PG, Long L, Wilkins MR et al. cAMP phosphodiesterase inhibitors potentiate effects of prostacyclin analogs in hypoxic pulmonary vascular remodelling. Am J Physiol Lung Cell Mol Physiol 2005; 288: L103-L115
11. Rosenkranz S, Kazlauskas A. Evidence for distinct signaling properties and biological responses induced by the PDGF receptor a and b subtypes. Growth Factors 1999; 16: 201-216
12. Schermuly RT, Dony E, Ghofrani HA et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005; 115: 2811-2821
13. Souza R, Sitbon O, Parent F, Simonneau G, Humbert M. Long term imatinib treatment in pulmonary arterial hypertension. Thorax 2006; 61: 736
14. Vantler M, Caglayan E, Zimmermann WH, Bäumer AT, Rosenkranz S. Systematic evaluation of anti-apoptotic growth factor signaling in vascular smooth muscle cells: Only phosphatidylinositol 3′-kinase is important. J Biol Chem 2005; 280: 14168-14176